FDA Extends Leqembi Iqlik Review, Setting New PDUFA Date for August 24
Event summary
- FDA extended the review period for Leqembi Iqlik's sBLA by three months, setting a new PDUFA date of August 24, 2026.
- The extension follows a major amendment request for additional information, though no approvability concerns have been raised.
- Leqembi Iqlik is a once-weekly subcutaneous injection for early Alzheimer's disease, following FDA approval of its maintenance dosing regimen in August 2025.
- Leqembi is already approved in 53 countries, with Eisai and BioArctic preparing for joint commercialization in the Nordic region.
The big picture
The extension of the PDUFA date for Leqembi Iqlik reflects the FDA's cautious approach to novel Alzheimer's treatments, even as Leqembi gains global regulatory approvals. Eisai and BioArctic's collaboration underscores the strategic importance of subcutaneous administration in expanding treatment accessibility. The broader biotech sector will watch closely as the regulatory landscape for Alzheimer's therapies continues to evolve.
What we're watching
- Regulatory Approval
- Whether the FDA's request for additional information will delay or complicate Leqembi Iqlik's approval process.
- Market Expansion
- The pace at which Eisai and BioArctic can scale commercialization efforts in the Nordic region and beyond.
- Clinical Development
- How ongoing clinical studies, such as AHEAD 3-45 and Tau NexGen, will impact the long-term viability of Leqembi as a treatment option.
Related topics